NEWSROOM
Press Releases by Agendia
News
Press Releases
Molecular Subtyping Can Help Determine Prognosis and Chemotherapy Benefit in Colorectal Cancer Patients
CHICAGO – Molecular subtyping can help predict outcomes and chemotherapy benefit in patients with colorectal cancer, according to a presentation at the annual conference of the American Society of Clinical Oncology (ASCO). This scientific poster Read More
Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
IRVINE, CA, May 31, 2013 – Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Read More
Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
IRVINE, CA, May 2, 2013 – Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone. The MammaPrint Read More
Study shows half of early-stage breast cancer patients may be able to avoid chemotherapy
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
MammaPrint breast cancer test ID’s women who can avoid chemotherapy
KARE, Minneapolis-St.Paul-2013 This TV report tells how you can “know your breast cancer” better through this genomic, personalized medicine test, which is part of the Symphony suite of breast cancer tests.
Study Shows Half of Early-Stage Breast Cancer Patients May Safely Avoid Chemotherapy
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 4, 2013 – The MammaPrint breast cancer test can dramatically reduce the number of women who need to undergo chemotherapy to treat the disease, according to a newly Read More